The diagnosis of rare diseases and the availability of drugs to treat them remain significant challenges to the healthcare system in China. Although several strategies have been employed to promote the identification and treatment of rare diseases, they remain under-recognized in this region. Patient advocacy groups, other non-profit organizations, academic institutions and pharmaceutical companies have recently made significant efforts towards increasing the awareness and understanding of rare diseases. Nevertheless, China is still in the early stages of enacting policies related to rare diseases and regulation of muchneeded orphan drugs. Unlike in the US, EU, Japan and Taiwan, there is currently no specific nationwide legislation for orphan drugs in China. Furthermore, Chinese public health insurance does not cover the medical requirements of most rare disease patients.
Download the whitepaper now to find out more about:
-
Legislation relating to rare diseases
-
Laws and regulations relating to rare diseases worldwide
-
Social support and advocacy to increase rare disease awareness
-
Research support in rare diseases
-
Myasthenia Gravis (MG) in China
-
Economic incentives for orphan drug access
-
Pilot project to improve healthcare in rare diseases
-
Challenges of rare diseases and their treatment
...and much more!
Get your copy here!